Expects FY25 revenue to increase from 2024, FY24 revenue $792.3M. “GoodRx (GDRX) delivered a solid financial quarter and strong execution across our key initiatives,” said Chris McGinnis, Chief Financial Officer and Treasurer of GoodRx. “Total revenue of $196 million increased slightly versus the prior year, with pharma manufacturer solutions seeing 35% growth year-to-date when compared to the first nine months of 2024.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX: